Safety and Efficacy of ALC in Breast Cancer in Subjects With Fatigue
The objective of this study is to evaluate the efficacy and safety of ALC in the treatment of non-anemic, breast cancer subjects who develop moderate or severe fatigue during adjuvant radiotherapy.
Breast Cancer
DRUG: ALC and Placebo
Change of BFI as evaluated from Baseline to Final Visit, 16 weeks
Changes in Health-Related Quality of Life (HQoL) outcomes using Medical Outcomes Study Short Form Health Status Profile 12 items (MOS-SF 12, 16 weeks
The objective of this study is to evaluate the efficacy and safety of ALC in the treatment of non-anemic, breast cancer subjects who develop moderate or severe fatigue during adjuvant radiotherapy